Cycle helmet ownership and use; a cluster randomised controlled trial in primary school children in deprived areas

D Kendrick, S Royal, on behalf of the “Lids for Kids” project team

Aims: To assess the effectiveness of two different educational interventions plus free cycle helmets, in increasing cycle helmet ownership and use.

Methods: A cluster randomised controlled trial was carried out in 28 primary schools in deprived areas of Nottingham, involving 1213 year 5 schoolchildren (age 9 and 10). Children received either a helmet + educational pack (educational pack and order form for free cycle helmet) or a helmet + multifaceted intervention (educational pack, order form for free cycle helmet, school assembly, lesson devoted to cycle helmet education, and an invitation to a school based cycling event).

Results: The helmet + educational pack was as effective as the helmet + multifaceted intervention in terms of helmet ownership (OR 1.51, 95% CI 0.50 to 4.58) and wearing (OR 0.98, 95% CI 0.57 to 1.68). Helmet ownership significantly increased from baseline with both interventions, and wearing significantly increased from baseline with the helmet + educational pack. The interventions reduced the inequality in helmet ownership between children residing in deprived and non-deprived areas that had been present prior to the study.

Conclusions: An educational pack plus a form to order a free cycle helmet is an effective way of increasing bicycle helmet ownership and use and reduces inequalities in helmet ownership among children in deprived areas. Further work is needed to determine the length of the effect of such interventions.

Bicycle helmets afford protection against head and brain injuries to wearers of all ages involved in all types of crash, whether or not another vehicle is involved. Although childhood cycle injuries appear to be reducing in incidence, there were still more than 7500 children under 16 admitted to NHS hospitals between 1991 and 1995 with a list of related head injuries.

There is a steep social class gradient in mortality from pedal cycle injury, with children from social class V having a mortality rate four times higher than children from social class I. Hospital admission rates for cycling injuries are 61% higher among children from deprived than affluent areas. We have recently shown that fewer children in deprived areas own cycle helmets than in affluent areas, but that once a child owns a helmet, helmet wearing is not related to deprivation. Previous work suggests the cost of a helmet can act as a barrier to its purchase, and cycle helmet subsidies have been shown to be effective in increasing helmet use among children in low income areas.

At present there are relatively few randomised controlled trials of interventions to promote helmet use in children without enacting legislation. Four of the trials examined the effectiveness of physician counselling. Two of these found no effect on helmet ownership, one found counselling plus a helmet discount coupon increased helmet purchase, and the fourth found counselling increased self reported helmet wearing. A further trial assessed the effect of co-payments for helmets in addition to physician counselling and found co-payments increased self reported helmet wearing as effectively as providing free helmets. A school based trial found that subsidised helmets increased observed helmet wearing rates and that education without subsidised helmets had no effect. Finally a trial of a school based bicycle skills training programme found no effect on self reported helmet use. More non-randomised studies exist, many of which used complex multifaceted interventions. At present it is not clear whether some elements of these interventions are more effective than others, and if so, which elements this applies to. Several studies have also assessed the effect of the interventions by social group, finding conflicting results. There is therefore a need to determine which elements of a cycle helmet programme are effective, and whether such programmes are equally effective in children from different social groups. This information is important to ensure effective use of resources for injury prevention and the reduction of health inequalities.

The objectives of this study were therefore to evaluate the effectiveness of two different educational interventions in addition to free cycle helmets in increasing cycle helmet ownership and wearing among 9 and 10 year olds from deprived areas of Nottingham, and to examine whether the effect differed by social group.

METHODS

All year 5 children registered at participating schools were eligible to take part in the study. All 120 primary schools in deprived areas in Nottingham (defined as a ward with a Townsend score >0) were invited to participate. Twenty nine schools participated in the study, and a further school acted as a pilot for the baseline data collection and interventions.

Interventions

The study compared two different educational interventions. Intervention 1 comprised an educational pack plus a form to order a free helmet. Intervention 2 comprised an educational pack, a form to order a free helmet, an assembly, one lesson devoted to cycle helmet education, and an invitation to a cycling event. The educational pack included a road safety quiz, two educational booklets, a cycling fact sheet produced by Nottingham City Council Road Safety and Environmental Services Department, a helmet order form for the child to choose from five helmet designs, and a covering letter encouraging parent participation.
to complete the quiz with their parents and return it to the school with the helmet order form. Helmets were delivered to the schools direct from the manufacturer with written instructions on how to fit the helmet. The assembly, undertaken by a local doctor included an explanation of the effect of a head injury on a child’s life, a video of a local child with a head injury, and an egg drop with and without a helmet. The objectives of the cycle helmet lesson were to increase understanding of how an injury affects the brain and its functioning, the need for protection of the brain when engaging in risky activity, and the impact a head injury can have on the life of a child and their family. Teachers were provided with a lesson plan, the Bicycle Helmet Initiative Trust video Happy Birthday Paul with a list of questions and answers to lead discussion after the video, and a human skull. All children were invited to a cycling event at a local school where cycle control skills were demonstrated and children had the opportunity to try activities aimed at increasing their control over their bike. The interventions took place in June and July 2001.

The interventions were designed based on the findings from three focus groups held with local children aged 11–12 who had taken part in a cycle helmet project the previous year, and from a review of the literature, and was informed by advice from teachers, health promotion specialists, school nurses, road safety officers, the British Cycling Federation, paediatricians, accident and emergency department consultants, and general practitioners. It was piloted in one school not taking part in the project.

**Outcomes**

The primary outcomes for the study were the proportion of children owning and wearing a cycle helmet. These were assessed by anonymous self completion questionnaire, based on questions used in previous cycle helmet research, using two cross-sectional surveys; the baseline assessment took place in June 2001 and the follow up assessment in September 2001.

Observations of cycle helmet wearing were carried out to validate self reported helmet wearing. Only 2% of children in participating schools rode to school, hence we organised cycling events in four schools (two in each treatment group) two weeks following completion of the follow up questionnaire to observe helmet wearing. Children were invited to attend, and the invitation purposely did not make any specific mention of cycle helmets. A member of the research team observed the proportion of children riding bikes at the event who were wearing a helmet.

**Sample size**

The study had 80% power to detect a difference in the percentage of children owning a helmet from 81% to 90% between the two treatment groups, at the 5% significance level. The intra-class correlation coefficient (ICC) calculated from our sample was 0.09. It had 80% power to detect a difference in the percentage of children always wearing a helmet from 34% to 44.5%, at the 5% significance level. The ICC for helmet wearing calculated from our sample was 0.04.

**Randomisation**

Participating schools were stratified by Townsend score into three strata (0.1–2.99, 3.0–6.99, and ≥ 7). Schools were randomly allocated within each stratum to treatment group. One member of the research team generated the allocation schedule, and a second member of the research allocated the schools to treatment group team blind to the identity of each school.

**Blinding**

It was not possible to blind the schools or the investigators to treatment group. The data were analysed blind to treatment group.

**Primary analyses**

Comparability of treatment groups at baseline was assessed informally. Data were analysed using STATA version 7, SPSS version 11.0, and MLwiN version 1.1. Analyses were undertaken on an intention to treat basis. The primary analysis of helmet ownership and always wearing a helmet was undertaken using t tests weighted by the number of children in each school. We have adjusted for baseline helmet ownership and for factors associated with helmet ownership or wearing, where there were large baseline differences between treatment groups using random effects logistic regression (MLwiN) to adjust for clustering.

**Secondary analyses**

To assess whether the helmet + educational pack or the helmet + multifaceted intervention was more effective for children living in deprived areas we added a term for the interaction between treatment group and deprived area to the random effects logistic regression. Prior to the trial we reported that fewer children in deprived areas owned a helmet. To assess whether the interventions reduced this inequality, we examined the change in the relation between school level helmet ownership and deprivation at baseline and at follow up using linear regression. We used the difference in the proportion of children in each school owning a helmet (follow up proportion – baseline proportion) as the dependent variable and the median Townsend score for the school as the explanatory variable. Assumptions for the regression analyses were checked by examining plots of residuals.

Changes from baseline in helmet ownership and wearing were assessed using paired t tests, weighted by the number of children in each school.

**RESULTS**

Figure 1 shows the progress of the 29 randomised schools and their 1213 children through the trial. Table 1 shows the characteristics of treatment groups at baseline. More children in the helmet + multifaceted intervention group were male, lived in a deprived area, and had been encouraged by their family to wear a helmet. Fewer children in the helmet + multifaceted intervention group used their bike to ride to friends and owned a helmet before the interventions started.

**Primary analyses**

Table 2 shows the primary outcomes. We found no significant difference between the treatment groups in either helmet ownership or wearing. The unadjusted odds ratio for cycle helmet ownership comparing the helmet + multifaceted intervention with the helmet + educational pack was 1.54 (95% CI 0.62 to 3.84) and 1.51 (95% CI 0.50 to 4.38) after adjusting for helmet ownership at baseline, residence in deprived area, frequency of riding bike, parental warning about danger of not wearing a helmet, and family encouragement to wear helmet. The unadjusted odds ratio for helmet wearing was 1.05 (95% CI 0.65 to 1.68) and 0.98 (95% CI 0.57 to 1.68) after adjusting for family encouragement to wear a helmet, best friend wearing a helmet, uses bike to ride to friends, and thinks comfort of helmet is important.

**Secondary analyses**

The helmet + multifaceted intervention did not appear to be more effective than the helmet + educational pack among children living in a deprived area (helmet ownership...
All primary schools with Townsend score >0 invited to participate n = 120
Excluded schools n = 91
  Schools not responding to intervention n = 85
  Did not meet eligibility criteria n = 2 (only enrolled children aged 5–7)
  School declined to participate n = 3
  School used as pilot for surveys and intervention n = 1
Schools agreeing to participate and eligible n = 29
  Helmet + educational pack n = 15
  Helmet + multifaceted intervention n = 14
  Children in brief intervention schools n = 704
  Children in intensive intervention schools n = 522
  1 school withdrew prior to baseline assessment (13 children)
  Children remaining in helmet + educational pack schools n = 691

Baseline assessment
  Children in school on day of survey n = 597
  Completed baseline assessment 100% (n = 597)
  Schools received intervention n = 14
  Children received helmet n = 351
  Children returned road safety quiz n = 324
  Children in school on day of survey n = 464
  Completed baseline assessment 100% (n = 464)
  Children received intervention n = 14
  Children received helmet n = 352
  Children returned road safety quiz n = 269
  Children attended cycling event n = 60

Follow up assessment
  Children in school on day of survey n = 605
  Completed follow up assessment 76.7% (n = 464)
  Schools received intervention n = 14
  Children received helmet n = 352
  Children attended cycling event n = 60
  Children in school on day of survey n = 459
  Completed follow up assessment 97.8% (n = 449)

p = 0.90, helmet wearing p = 0.72). We therefore combined the data from both treatment groups to examine the relation between deprivation and helmet ownership at baseline and at follow up. Figure 2 shows that as the degree of deprivation increased the proportion of children owning a helmet decreased, and that this was more marked at baseline than at follow up (b = 0.027, 95% CI 0.004 to 0.050, p = 0.026). Table 3 shows a significant increase from baseline helmet ownership in both groups and in helmet wearing in the helmet + educational pack group.

DISCUSSION
This study is the first randomised controlled trial aimed at increasing cycle helmet use in the UK. It has shown that a free helmet and an educational pack were as effective as a free helmet plus a multifaceted intervention in increasing helmet ownership and wearing in the short term. Both interventions reduced the inequality in helmet ownership between children residing in deprived and non-deprived areas that had been present prior to the study. This is important as we have previously shown that once a helmet is owned, wearing rates do not differ between children residing in deprived and non-deprived areas.

Limitations of the study
Our study did not include a group that did not receive any intervention because we know from previous research that providing or subsidising helmets increases ownership and that education without subsidised helmets does not. We think it is highly unlikely that helmet ownership would increase from 50% to 80% over the three month study period for reasons other than the interventions, as there were no other cycle helmet schemes targeted at children from these schools during this time period.

We used self reported helmet ownership and wearing as the primary outcome measures, but self reports may not accurately reflect actual wearing rates. Observations of helmet wearing are usually used to validate self reported wearing, but as the intervention was restricted to a single...
year group within each school, and only 2% of children rode to school, we were limited in how we could conduct observations. We piloted observations with a year 5 teacher from participating schools and a researcher driving in the catchment area of the school, with the teacher identifying year 5 children from the school. We observed 99 children during five observations, only nine of which belonged to year 5, making it unfeasible to observe sufficient children within the time scale and budget of the trial. We therefore organised cycling events at schools in both treatment groups after the follow up questionnaire to observe helmet wearing. The observations found higher wearing rates than self reported rates of always wearing a helmet. These findings are similar to a large study that observed more than 900 children riding and performed classroom surveys of more than 8000 children; it found classroom self reported always wearing rates (15%) were lower than observed wearing rates (20%), self reported use of helmet on day of survey (26%), or parent report of child always wearing a helmet (37%). This suggests classroom self reported rates of always wearing a helmet may be the most conservative estimates of helmet wearing rates.

Table 1  Characteristics of treatment groups at baseline (missing values)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Helmet + educational pack (n = 597)</th>
<th>Helmet + multifaceted intervention (n = 464)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male)</td>
<td>285 (47.7)</td>
<td>248 (53.5)</td>
</tr>
<tr>
<td>Resides in deprived area</td>
<td>230 (44.4) [94]</td>
<td>288 (55.6) [67]</td>
</tr>
<tr>
<td>Owns bike</td>
<td>556 (93.1)</td>
<td>399 (86.0)</td>
</tr>
<tr>
<td>Rides bike*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 or more days per week</td>
<td>300 (54.6) [7]</td>
<td>209 (53.6) [9]</td>
</tr>
<tr>
<td>3 days a week or less</td>
<td>249 (45.4)</td>
<td>181 (46.4)</td>
</tr>
<tr>
<td>Rides bike*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To and from school</td>
<td>18 (3.2)</td>
<td>5 (1.3)</td>
</tr>
<tr>
<td>To visit friends</td>
<td>296 (53.2)</td>
<td>188 (47.2)</td>
</tr>
<tr>
<td>For fun</td>
<td>489 (88.0)</td>
<td>348 (87.2)</td>
</tr>
<tr>
<td>Only when has to</td>
<td>62 (11.2)</td>
<td>25 (6.3)</td>
</tr>
<tr>
<td>For sport</td>
<td>187 (33.6)</td>
<td>149 (37.3)</td>
</tr>
<tr>
<td>Encouraged by family members to</td>
<td>310 (55.8)</td>
<td>185 (46.4)</td>
</tr>
<tr>
<td>wear helmet*</td>
<td>346 (62.4) [17]</td>
<td>266 (70.2) [20]</td>
</tr>
<tr>
<td>Told about dangers of not wearing helmet by:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>School nurse</td>
<td>44 (7.0)</td>
<td>51 (11.8)</td>
</tr>
<tr>
<td>Teacher</td>
<td>407 (64.9)</td>
<td>298 (68.7)</td>
</tr>
<tr>
<td>Doctor</td>
<td>109 (17.4)</td>
<td>74 (17.1)</td>
</tr>
<tr>
<td>Policeman</td>
<td>166 (26.5)</td>
<td>103 (23.2)</td>
</tr>
<tr>
<td>Road safety officer</td>
<td>380 (60.6)</td>
<td>290 (66.8)</td>
</tr>
<tr>
<td>Best friend wears helmet</td>
<td>217 (38.0) [26]</td>
<td>159 (35.5) [16]</td>
</tr>
<tr>
<td>Had accident on bike requiring medical attention</td>
<td>104 (17.4)</td>
<td>96 (20.7)</td>
</tr>
<tr>
<td>Wears helmet when riding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Always</td>
<td>86 (28.3) [6]</td>
<td>56 (30.6) [2]</td>
</tr>
<tr>
<td>Sometimes</td>
<td>154 (50.7)</td>
<td>80 (43.7)</td>
</tr>
<tr>
<td>Never</td>
<td>64 (21.1)</td>
<td>47 (25.7)</td>
</tr>
</tbody>
</table>
% of those who own bike; †% of those owning helmet.

Table 2  Number of children owning and always wearing a helmet by school and treatment group post-intervention (percentage)

<table>
<thead>
<tr>
<th>Owns a helmet</th>
<th>Always wears a helmet</th>
</tr>
</thead>
<tbody>
<tr>
<td>School number</td>
<td>School number</td>
</tr>
<tr>
<td>Helmet + multifaceted intervention</td>
<td>Helmet + educational pack</td>
</tr>
<tr>
<td>1</td>
<td>38/47 (81)</td>
</tr>
<tr>
<td>2</td>
<td>18/18 (100)</td>
</tr>
<tr>
<td>3</td>
<td>15/29 (52)</td>
</tr>
<tr>
<td>4</td>
<td>12/15 (80)</td>
</tr>
<tr>
<td>5</td>
<td>12/13 (92)</td>
</tr>
<tr>
<td>6</td>
<td>20/22 (91)</td>
</tr>
<tr>
<td>7</td>
<td>20/20 (100)</td>
</tr>
<tr>
<td>8</td>
<td>17/24 (71)</td>
</tr>
<tr>
<td>9</td>
<td>40/50 (80)</td>
</tr>
<tr>
<td>10</td>
<td>30/40 (75)</td>
</tr>
<tr>
<td>11</td>
<td>55/55 (100)</td>
</tr>
<tr>
<td>12</td>
<td>22/22 (100)</td>
</tr>
<tr>
<td>13</td>
<td>5/9 (56)</td>
</tr>
<tr>
<td>14</td>
<td>10/10 (100)</td>
</tr>
<tr>
<td>Mean percentage across schools (SE)*</td>
<td>84.0 (4.2)</td>
</tr>
<tr>
<td>Difference between means (95% CI)</td>
<td>3.0 (0.98)</td>
</tr>
</tbody>
</table>

*Weighted by number of children in each school.
results. If non-responders in the helmet + educational pack group were less likely to own or wear helmets than responders, this would tend to underestimate the effect of the helmet + multifaceted intervention. The worst case scenario is that helmet wearing rates among the non-responders in the helmet + educational pack group did not increase from those at baseline. Using the ownership and wearing rates for each school at baseline, we estimated the numbers of non-responders in each school owning and wearing a helmet at follow up. Under this scenario, the helmet + educational pack group helmet ownership rate at follow up would reduce to 75% and the percentage always wearing a helmet to 33%. The differences between these figures and the helmet + multifaceted intervention group ownership and wearing rates would not alter the conclusions we have drawn from this study.

Finally we have only been able to show short term effects of the interventions used in this study. Future research should consider the use of a longer follow up period to determine the length of time for which the interventions remain effective and to assess whether helmet wearing continues into the teenage years, as wearing rates are usually lower in this age group.26 32–37

**How this study compares to previous studies**

Several studies have assessed the impact of educational programmes plus subsidised helmets in low income communities.14 16 19 38 Two showed increased helmet use among low income children,16 34 one found requesting parents to pay a small amount towards helmets was as effective as providing free helmets in increasing helmet use,14 and the fourth found subsidised helmets did not increase helmet use among children from low income families.19 Our findings add weight to the three studies reporting the positive effect of helmet subsidies in low income communities, and confirm these findings in a UK context.

Studies that have undertaken subgroup analyses assessing the impact of educational interventions plus cycle helmet provision by social group have produced mixed results. One study found the intervention was associated with higher helmet wearing rates among children from low income communities,9 while others found the intervention to be less effective in low income communities.7 14 24 We did not find a significant difference in the effectiveness of the interventions by residence in a deprived area, which is encouraging; however, the study was not designed to be adequately powered to detect such a difference, so care must be taken in interpreting these results.

**Implications for practice and research**

Most reported helmet promotion programmes have employed multifaceted interventions and it is often not clear how each component contributes to the overall effectiveness of the programme. This study has shown that the many time consuming (and potentially expensive) components of multifaceted intervention conferred little if any advantage in terms of helmet ownership or wearing over a simpler intervention, at least in the short term. In addition the interventions reduced the inequality in helmet ownership associated with living in a deprived area. Bicycle helmets are effective in reducing head and brain injuries and have been shown to be cost effective.39 Primary Care Trusts and other agencies wishing to reduce both childhood injuries and inequalities should consider providing free helmets with an educational pack. More research is necessary to determine the length of the observed effect, particularly with respect to helmet wearing into the teenage years. Concerns have been expressed that increasing cycle helmet use may be associated with an increase in risk taking by helmeted cyclists40–42 and a reduction in cycling and its associated health benefits.43 Agencies working to improve child health will need to implement other interventions in addition to cycle helmet promotion to achieve maximum injury reduction. Similarly maximising childhood exercise will require the promotion of exercise in its broadest sense, not just cycling.

**ACKNOWLEDGEMENTS**

We would like to thank Kath Needham the project administrator, plus the members of the “Lids for Kids” project team who were Dr David Thomas, Dr Frank Coffey, Dr Stephanie Smith, Ms Kate Fletcher, Mr Roger Whitfield, Ms Hazel Hoskyns, Ms Sue Spanwick, and Ms Pauline Brown. We would also like to thank the children, teachers, and administrative staff at the participating schools and Ms Carol Coupland for statistical advice.

**Authors’ affiliations**

D Kendrick, S Royal, Division of General Practice, University Park, Nottingham, UK

Funding: Nottingham Health Authority

**REFERENCES**


Cycle helmet ownership and use

40 Thompson DC, Thompson RS, Rivara FP. Risk compensation theory should be subject to systematic reviews of the scientific evidence. Inj Prev 2001;7:86–8.
Radiological sign of a long line in the ascending lumbar vein

We would like to draw attention to a useful radiological sign indicating that a percutaneous central venous catheter may be in the ascending lumbar vein. In our neonatal unit there have been two confirmed cases where the ascending lumbar vein had inadvertently been cannulated. In both these cases a loop in the line had been noted in the region of the ilio-femoral vein (see figs 1 and 2). This “looping” or bend in the line is also seen in the picture recently published by De,5 and in other papers.1–4

That this complication occurs almost exclusively on the left1 has been attributed to the unique anatomy of the left ilio-femoral vein compared to the right.1 We believe that the local anatomy of the left ilio-femoral vein may also explain why the line loops when inadvertently entering the left ascending lumbar vein (fig 3). One can appreciate that, when the ascending lumbar vein is seen on the lateral1 and lateral-oblique view,1 and compared with the anterior-posterior view, the vein can be seen to descend into the pelvis and then enter the ascending lumbar vein at an angle. On an x ray the line will then project a loop or bend.

Figure 1

Figure 2


Another factor that may contribute to the appearance of the loop or bend is that it is probably difficult to advance the line up the narrow ascending lumbar vein, and therefore when trying to thread the line to its calculated length the line will “buckle” at this point.

Any loop or bend of a contrast filled line in the left ilio-femoral region should be regarded as a sign that the line has entered the ascending lumbar vein and pull the line back because the lumbar venous plexus will not always be visualised with contrast. There are serious complications of an unreco gnised malpositioned long line.6 We feel that awareness of this radiological sign would facilitate early recognition and would prevent serious morbidity.

B C Schoonakker, D Harding
Department of Neonatology, UHBT, St Michael’s, Bristol BS2 8BJ, UK; bernard.schoonakker@uhbt.swest.nhs.uk

doi: 10.1136/adc.2005.072595

Competing interests: none declared

References


Changing incidence of respiratory presentations in primary care fact or artefact?

Recently reported declines in asthma morbidity7 may be difficult to interpret as they could reflect not only changes in incidence, but also changing disease severity, patient expectations, healthcare provision, and efficacy of pharmacological management. Indeed, it has been suggested that general practitioners may choose differing diagnostic labels for respiratory disease to justify prescribing medication.7

In view of these apparent inconsistencies, we used 37 practices taking part in the Scottish Continuous Morbidity Recording project (CMR) to determine possible changes in diagnostic fashion. Changes in the yearly age specific incidence (per 1000 population) were ascertained for the recording of diagnoses and symptoms including asthma, wheeze, and other respiratory illnesses including acute bronchitis, bronchiolitis, lower respiratory tract infection (LRTI), cough, chest infection, and acute respiratory infections combined (Read codes (version 2) used listed in table 1). The CMR project’s data collection processes have been described previously.7 Two child age groups were defined, namely those aged under 5 years of age (n = 12 693 children) and those aged 5–14 years (n = 30 165 children). Trends of disease incidence for six 12-month periods starting 31 March 1996 and ending 31 March

www.archdischild.com
Table 1: Respiratory illnesses studied; Read codes

<table>
<thead>
<tr>
<th>Respiratory disease</th>
<th>Read code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute bronchitis</td>
<td>H060 and below</td>
</tr>
<tr>
<td>Acute respiratory infections</td>
<td>H0 and below</td>
</tr>
<tr>
<td>Asthma</td>
<td>H33 and below</td>
</tr>
<tr>
<td>Bronchiolitis</td>
<td>H061 and below</td>
</tr>
<tr>
<td>Chest infection</td>
<td>H0620</td>
</tr>
<tr>
<td>Group</td>
<td>H064</td>
</tr>
<tr>
<td>Lower respiratory tract infection</td>
<td>H0621</td>
</tr>
<tr>
<td>Wheeze</td>
<td>1737, R0609</td>
</tr>
</tbody>
</table>

Table 2: Annual incidence of asthma and wheeze and lower respiratory disease studied; Read codes

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Year</th>
<th>1st diagnoses</th>
<th>Incidence per 1000</th>
<th>95% CI</th>
<th>Lower</th>
<th>Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under 5 years old</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>May 2000</td>
<td>259</td>
<td>19.7</td>
<td>17.5</td>
<td>22.3</td>
<td></td>
</tr>
<tr>
<td>Wheeze</td>
<td>May 2000</td>
<td>211</td>
<td>16.6</td>
<td>14.5</td>
<td>19.0</td>
<td></td>
</tr>
<tr>
<td>Diagnosed with both</td>
<td>May 2000</td>
<td>211</td>
<td>16.6</td>
<td>14.5</td>
<td>19.0</td>
<td></td>
</tr>
</tbody>
</table>

| 5–14 years old          |      |                   |                    |        |       |       |
| Asthma                  | May 2000 | 259               | 19.7               | 17.5   | 22.3  |
| Wheeze                  | May 2000 | 211               | 16.6               | 14.5   | 19.0  |
| Diagnosed with both     | May 2000 | 211               | 16.6               | 14.5   | 19.0  |

Overall, there was an increase in incidence rates for those recorded as having any one study disease or symptom (p < 0.001).

Acknowledgements
The authors are grateful to the general practitioners who provided practice data to the Primary Care Clinical Informatics Unit–Research.

C R Simpson, A J Lee, M W Taylor
Department of General Practice & Primary Care, The University of Aberdeen, Scotland, UK

P J Helms
Department of Child Health, University of Aberdeen, Scotland, UK

Correspondence to: Dr C R Simpson, Department of General Practice & Primary Care, Forresthill Health Centre, Westburn Road, The University of Aberdeen, Aberdeen AB25 2AY, Scotland, UK; c.simpson@abdn.ac.uk
doi: 10.1136/adc.2004.063834

Competing interests: Peter J Helms has performed consultancies for Glaxo-Wellcome, Astra-Zeneca, and Merck Sharp & Dohme. Michael Taylor, Amanda Lee, and Colin Simpson have no competing interests.

References

Patient choice in medicine taking: religious sensitivities must be respected
Children often do not have choice in medicine taking, as it is typically their parents who agree, on their behalf, to receive prescribed treatments. Exploring parents’ (and wherever possible also children’s) beliefs about choice of medication is however important, particularly so when strong religious beliefs about

www.archdischild.com
contents of medications may be present, as a failure to do so may result in unintended harm and negatively impact on compliance.

In a multicultural context, it is essential that prescribers have a minimal level of awareness of parent’s religious sensitiveness so that these can be considered when prescribing (table 1). Jehovah’s Witnesses, for example, may choose to avoid blood derived products. Jewish law forbids any oral use of medication containing glycerol, stearates, lactose, and porcine products. Similarly, Hindus and Sikhs may be offended by medication containing animal products, particularly bovine derived products (for example, gelatine containing capsules). Islamic rulings that prohibit any systemic ingestion of pork or alcohol also need to be considered in the context of prescribing decisions involving Muslims.*

A practical way of ensuring that health professionals have sufficient information about treatment options available would be for the British National Formulary to clearly indicate which preparations contain blood, animal, and alcohol derivatives, and, where possible, suggest suitable alternatives. The proposed electronic health records will facilitate the seamless sharing of patient information among multiple healthcare providers. This will therefore offer an additional systematic approach for routinely collecting information, and through use of “prescribing alerts” can help inform clinicians about patient preferences in relation to medications.

But beliefs need to be balanced against clinical need. Recognising that many religious traditions offer a degree of relaxation of their respective laws in extenuating circumstances, there may be a need to work pragmatically with faith leaders to find acceptable compromises in cases where suitable treatments or treatment regimens do not exist, for example in the case of pancreatic preparations, which are all porcine in origin (table 1).

Stereotyping must however be avoided. Arguably, even more important than knowledge of the main tenets of different faiths and access to information about the constituents of medicines then, is that prescribers have the skills and attitudes to explore patients’ own beliefs and preferences during prescribing consultations. Parents and children are not passive recipients of prescribing decisions; they have their own views which are a key influence on whether and how they take medications and these must be respected.

<table>
<thead>
<tr>
<th>Blood, bovine, and pork derived medications (generic and proprietary names)</th>
<th>Alternative preparations (generic and proprietary names)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>Crystalloid e.g. saline</td>
</tr>
<tr>
<td>Factor VIII</td>
<td>Recombinant factor VIII</td>
</tr>
<tr>
<td>Bovine</td>
<td>Amoxicillin (Amoxicillin)</td>
</tr>
<tr>
<td>Beef insulin</td>
<td>Recombinant insulin</td>
</tr>
<tr>
<td>Omeprazole (Losec)</td>
<td>Omeprazole (MUPS) dispersible tablets</td>
</tr>
<tr>
<td>Pork</td>
<td>Cefalexin palmitate (Eaxsurf)</td>
</tr>
<tr>
<td>Portant alfa (Curosurf)</td>
<td>MMR vaccine (Priorix)</td>
</tr>
<tr>
<td>MMR vaccine (MMR-II)</td>
<td>Heparin (Arixtra)</td>
</tr>
<tr>
<td>Heparin calcium (Calciparine)</td>
<td>Insophane insulin (Human insulinadur)</td>
</tr>
<tr>
<td>Pancreatin (Pancrease)</td>
<td>No alternative</td>
</tr>
</tbody>
</table>

References


Lessons from an unsuccessful local attempt to tackle childhood overweight and obesity

While we greatly enjoyed Mary C J Rudolph’s “Best Practice” article on “The Obese Child”, we cannot agree with her conclusion that obesity fulfills most of the criteria for a condition that justifies screening. Our own local experience in Solihull, West Midlands, might illustrate this point.

Using a grant from the Children’s Fund (www.cypu.gov.uk/corporate/childrenstrust/index.cfm) we aimed to set up a “Fit Club” serving children aged 7–11 in seven wards in Solihull, with DETRI deprivation indices ranging from 7.53 to 54.49. All seven wards contain enumeration districts with deprivation indices in the worst 15% of the country.

We attempted to recruit 20 children, for an initial consultation phase, in which they and their families would be able to discuss with our multidisciplinary team the kinds of services they would like to tackle the child’s weight. They would be able to try out various exercise programmes if they wished, as well as receiving dietetic advice, and as an incentive we also offered £10.00 worth of fresh fruit and vegetables. The only criterion for recruitment was that the child should be perceived to have a weight problem both by their family and professionals.

We attempted to recruit children via contact with school nurses, recommendation from general practitioners, and an advertisement in the local paper. To our disappointment, we found that we were able to recruit only four children. GPs had forwarded seven names, of whom one actually made contact with the service, while the school nurses informally fed back that families felt that their child’s weight was not an issue on which they needed to take action. A final attempt at recruitment, based on one large primary school with support of teaching staff, was similarly completely unsuccessful. It would seem likely that a difference in perception of the seriousness of overweight and the need for action between parents and professionals explained our disappointing outcomes.

Our experience thus leads us to believe that detecting obese or overweight children by screening will not substantially alter the scale of these problems on a population basis, although services for those that do request them are clearly justified.

N Haisman, K A Matyka, A Stanton
Solihull Primary Care Trust, West Midlands, UK; haismann@hotmail.com

References


Author’s reply

Drs Haisman, Matyka, and Stanton describe their disappointing and frustrating experience of offering a programme for obese children. However this experience cannot be used to argue that screening would have no value.

My comment that obesity fulfills most of the criteria for screening was based on the fact that: it is a common condition with serious consequences; it can be identified in its early stages; and it is potentially reversible. If it was reversed the costs of identifying obese children would be more than offset by the savings in health care later. The big “but” is the one (and very major) problem that we cannot offer effective treatment. If we can resolve that, then undoubtedly we should be screening our school age population.

The Solihull experience is not universal. With current sympathetic media interest the climate is changing and we are finding that
families are seeking help. Our WATCH IT community based programme in Leeds has 65 children enrolled with good attendance and we now have a waiting list. Rather than dismiss the idea of screening at some point in the future, let us argue for more resources to develop clinically effective interventions.

M C J Rudolf
Department of Community Paediatrics, Belmont House, 3–5 Belmont Grove, Leeds LS17 8DR, UK; mary.rudolf@leedsth.nhs.uk

Patterns and risks in spinal trauma: the emergency transport perspective

The article by Martin and colleagues’ reviewing patterns and risks in spinal trauma highlights the increased incidence of spinal cord injury (SCI) and spinal cord injury without radiological abnormality (SCIWORA) in young children. They suggest that without clinical suspicion proper evaluation of the child’s spine may not occur, and refer to an audit by Skellet and colleagues that shows inadequate spinal immobilisation of paediatric trauma patients on arrival of the paediatric retrieval team.

Preventing secondary injury during transfer (movement of patients between hard surfaces in close proximity) and transport (patient movement between facilities) is particularly important.

There are a number of devices available to facilitate spinal immobilisation during transport and transport. These include spinal board (SB), vacuum mattress (VM), patslide, and scoop device in combination with traditional hard collar, blocks, and tapes to provide cervical spine immobilisation.

We carried out a survey to identify the current practices in immobilisation, transfer, and transport of the paediatric trauma patient with actual or potential SCI. Postal questionnaires were sent to the retrieval coordinators in 18 UK paediatric ICUs asking about methods of spinal immobilisation during transfer and transport of paediatric trauma patients and existence of guidelines for management of that population.

There was a 100% response rate (postal plus follow up phone calls to two centres). Only 27% (5/18) of retrieval services employed practice guidelines. For patient transfer, 27% (5/18) of retrieval services utilised a patslide device alone and 50% (9/18) utilised a patslide in combination with a vacuum mattress and/or spinal board (table 1). For patient transport, 67% (12/18) of services by a consistent approach (table 2). A spinal board, either alone or with padding, was used by 72% (13/18) of services for at least some of their patient transports.

One hundred per cent of services used the traditional triad of hard collar, sandbags/blocks, and tape/straps for maintaining cervical spine immobilisation.

As Martin et al have described, SCI and SCIWORA occur more frequently in younger children. Without an obvious radiological abnormality, these injuries may potentially be overlooked. Prevention of secondary injury is thus important during transport of at risk patients. Our survey illustrates that there is a lack of a consistent approach to spinal immobilisation during transfer and transport of paediatric trauma patients. There is also continuing use of spinal boards despite evidence that they should only play a role during extrication of patients in the pre-hospital setting and that vacuum mattresses may confer benefits in terms of patient safety and comfort.

The development of best practice guidelines may lead to a more consistent approach.

S A Russ, S W Hancock, M Quinton, R Moore Sheffield Children’s Hospital, UK

P Harrison
Princess Royal Spinal Injuries Unit, Sheffield, UK

Correspondence to: Dr S W Hancock, Consultant Paediatric Intensivist, Sheffield Children’s Hospital Retrieval Service, UK; stephen.hancock@sch.nhs.uk doi: 10.1136/adc.2005.072546

Competing interests: none declared

Table 1 Methods of patient transfer (n = 18)

<table>
<thead>
<tr>
<th>Method</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patslide alone</td>
<td>5</td>
</tr>
<tr>
<td>Patslide + VM</td>
<td>1</td>
</tr>
<tr>
<td>Patslide + SB</td>
<td>4</td>
</tr>
<tr>
<td>Patslide + VM or SB</td>
<td>4</td>
</tr>
<tr>
<td>Scoop + SB</td>
<td>2</td>
</tr>
<tr>
<td>VM alone</td>
<td>1</td>
</tr>
<tr>
<td>SB alone</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 2 Methods of patient transport in services with a consistent approach (n = 12)

<table>
<thead>
<tr>
<th>Method</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>VM alone</td>
<td>4</td>
</tr>
<tr>
<td>VM + SB</td>
<td>1</td>
</tr>
<tr>
<td>SB alone</td>
<td>2</td>
</tr>
<tr>
<td>SB + padding</td>
<td>2</td>
</tr>
<tr>
<td>Trolley only</td>
<td>1</td>
</tr>
</tbody>
</table>

Dapsone therapy for Henoch-Schönlein purpura: a case series

Henoch-Schönlein purpura (HSP), first recognised by Heberden in 1801, is a systemic, IgA mediated vasculitis of small vessels that is usually self-limited but may progress to gastrointestinal bleeding, intussusception, and nephropathy. A third of patients will experience recurrences. Currently treatment is confined to rest, analgesia, and steroids for refractory abdominal pain, and immunosuppressants for complications, especially renal disease.

Original reports, predominantly in adults, show that the symptoms of purpuric rash, abdominal pain, and arthritis in HSP respond to treatment with dapsone. Even though the first case of HSP treated with dapsone was reported in 1983, it is still not generally recognised as a treatment for HSP. We describe eight children in whom, because of the severity or persistence of their symptoms, treatment with dapsone was commenced from among 41 patients diagnosed with HSP from January 1992 to May 2004. All gained a clinical response from treatment with the most beneficial effect on the skin rash. The demographic characteristics of the patients and their presenting clinical features as well as treatment are shown in table 1. The rash improved within 3 days to 1 week of starting treatment with dapsone in all patients. Six of eight relapsed when treatment was stopped, but responded again to treatment. The side effects are dose related and uncommon at doses commonly used (1–2 mg/kg daily).

Dapsone, an antileprotic drug, used for a variety of dermatological conditions, appears to be of special value in diseases characterised by accumulation of neutrophils, notably with leucocytoclastic vasculitis, of which HSP is an example. There is evidence that it has antioxidant scavenger effects and may suppress the generation of toxic free radicals in neutrophils. It also inhibits prostaglandin D2 production and synthesis of IgG and IgA antibodies. It may also inhibit IgG–neutrophil interactions. Given the pathogenesis of HSP with IgA mediated vasculitis, treatment with dapsone represents an exciting form of treatment. The clinical course of our patients suggests that dapsone controls the cutaneous vasculitis rather than cures it. As steroids may mask the features of more ominous intestinal disease, dapsone can be a reasonable alternative. Nonetheless, to date there is no evidence of a positive effect on renal disease.

In conclusion, dapsone is a drug that may have a role in the treatment of HSP. In order to establish its usefulness it is necessary to conduct a multicentre, placebo, randomised controlled trial.

Informed consent was obtained from parents before starting treatment with dapsone.

H Iqbal, A Evans
Queen Elizabeth Hospital, London, UK

Correspondence to: Dr H Iqbal, Department of Paediatrics, Queen Elizabeth Hospital, Stadium Road, Woolwich, London SE18 4QH, UK; humai@hscil.co.uk doi: 10.1136/adc.2004.061598

Competing interests: none declared

References


2. Rosenblum ND, Winter HS. Steroid effects on the generation of toxic free radicals in neutrophils. It also inhibits prostaglandin D2 production and synthesis of IgG and IgA antibodies. It may also inhibit IgG–neutrophil interactions. Given the pathogenesis of HSP with IgA mediated vasculitis, treatment with dapsone represents an exciting form of treatment. The clinical course of our patients suggests that dapsone controls the cutaneous vasculitis rather than cures it. As steroids may mask the features of more ominous intestinal disease, dapsone can be a reasonable alternative. Nonetheless, to date there is no evidence of a positive effect on renal disease.

In conclusion, dapsone is a drug that may have a role in the treatment of HSP. In order to establish its usefulness it is necessary to conduct a multicentre, placebo, randomised controlled trial.

Informed consent was obtained from parents before starting treatment with dapsone.

H Iqbal, A Evans
Queen Elizabeth Hospital, London, UK

Correspondence to: Dr H Iqbal, Department of Paediatrics, Queen Elizabeth Hospital, Stadium Road, Woolwich, London SE18 4QH, UK; humai@hscil.co.uk doi: 10.1136/adc.2004.061598

Competing interests: none declared

References


2. Rosenblum ND, Winter HS. Steroid effects on the generation of toxic free radicals in neutrophils. It also inhibits prostaglandin D2 production and synthesis of IgG and IgA antibodies. It may also inhibit IgG–neutrophil interactions. Given the pathogenesis of HSP with IgA mediated vasculitis, treatment with dapsone represents an exciting form of treatment. The clinical course of our patients suggests that dapsone controls the cutaneous vasculitis rather than cures it. As steroids may mask the features of more ominous intestinal disease, dapsone can be a reasonable alternative. Nonetheless, to date there is no evidence of a positive effect on renal disease.

In conclusion, dapsone is a drug that may have a role in the treatment of HSP. In order to establish its usefulness it is necessary to conduct a multicentre, placebo, randomised controlled trial.

Informed consent was obtained from parents before starting treatment with dapsone.

H Iqbal, A Evans
Queen Elizabeth Hospital, London, UK

Correspondence to: Dr H Iqbal, Department of Paediatrics, Queen Elizabeth Hospital, Stadium Road, Woolwich, London SE18 4QH, UK; humai@hscil.co.uk doi: 10.1136/adc.2004.061598

Competing interests: none declared

References


2. Rosenblum ND, Winter HS. Steroid effects on the generation of toxic free radicals in neutrophils. It also inhibits prostaglandin D2 production and synthesis of IgG and IgA antibodies. It may also inhibit IgG–neutrophil interactions. Given the pathogenesis of HSP with IgA mediated vasculitis, treatment with dapsone represents an exciting form of treatment. The clinical course of our patients suggests that dapsone controls the cutaneous vasculitis rather than cures it. As steroids may mask the features of more ominous intestinal disease, dapsone can be a reasonable alternative. Nonetheless, to date there is no evidence of a positive effect on renal disease.

In conclusion, dapsone is a drug that may have a role in the treatment of HSP. In order to establish its usefulness it is necessary to conduct a multicentre, placebo, randomised controlled trial.

Informed consent was obtained from parents before starting treatment with dapsone.

H Iqbal, A Evans
Queen Elizabeth Hospital, London, UK

Correspondence to: Dr H Iqbal, Department of Paediatrics, Queen Elizabeth Hospital, Stadium Road, Woolwich, London SE18 4QH, UK; humai@hscil.co.uk doi: 10.1136/adc.2004.061598

Competing interests: none declared

References
Table 1  Demographic characteristics, presenting clinical feature, and treatment of the patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at presentation</td>
<td>22 m</td>
<td>8 y</td>
<td>8 y</td>
<td>5 ½ y</td>
<td>10 y</td>
<td>5 y</td>
<td>8 y</td>
<td>10 y</td>
</tr>
<tr>
<td>Sex</td>
<td>Ex</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Race</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>White</td>
<td>Vietnamese</td>
</tr>
<tr>
<td>Prognosis</td>
<td>–</td>
<td>Sore throat</td>
<td>–</td>
<td>–</td>
<td>Diarrhoea</td>
<td>Pustules</td>
<td>–</td>
<td>Tonsillitis</td>
</tr>
<tr>
<td>Presenting features</td>
<td>Miserable</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Rash</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Joint pain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Joint swelling</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vomiting</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Swollen testicle</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Haematuria</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Rectal bleeding</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Length of presentation</td>
<td>1 d</td>
<td>2 d</td>
<td>2 d</td>
<td>1 d</td>
<td>5 d</td>
<td>4 d</td>
<td>5 d</td>
<td>1 d</td>
</tr>
<tr>
<td>Presentation to treatment</td>
<td>10 d</td>
<td>14 m</td>
<td>4 m</td>
<td>18 m</td>
<td>5 m</td>
<td>8 d</td>
<td>11 d</td>
<td>1 m</td>
</tr>
<tr>
<td>Dose</td>
<td>1 mg/kg od</td>
<td>1.3 mg/kg od</td>
<td>1 mg/kg od</td>
<td>1.25 mg/kg od</td>
<td>0.75 mg/kg bd</td>
<td>1 mg/kg od</td>
<td>1 mg/kg od</td>
<td>0.5 mg/kg bd</td>
</tr>
<tr>
<td>Length of first course</td>
<td>6 d</td>
<td>7 d</td>
<td>4 d</td>
<td>4 w</td>
<td>10 d</td>
<td>7 d</td>
<td>14 d</td>
<td>10 d</td>
</tr>
<tr>
<td>Positive response</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Relapse after first course</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Total duration of treatment</td>
<td>6 d</td>
<td>7 d</td>
<td>4 d</td>
<td>2 ½ y</td>
<td>8 m</td>
<td>5 w</td>
<td>5 w</td>
<td>2 y</td>
</tr>
</tbody>
</table>


d, day; w, week; m, month; y, year; +, present; –, absent; od, once a day; bd, twice a day.


If community paediatricians did not exist, it would be necessary to invent them

Since 1991 there has been talk of abolishing community paediatrics as a specialty. At that time, a group of related specialties was proposed: a specialty of child development and rehabilitation (neuroisability); child protection would be subsumed into general paediatrics and there would be child public health doctors. Since then there has been a view among some paediatricians that community paediatricians should become the general paediatricians of the future. Dr Chambers’ recent article proposes a narrow view of community paediatrics, concentrating on chronic illness and confining its role to diagnosis and medical management. He rather misses the point.

The challenge of community paediatrics

Children do not come in neat packages, with diagnostic labels. They and their families need all their needs met. Hospital practice traditionally concentrates on the illness, not the patient, although this is becoming less with time and paediatricians have always been more holistic than adult counterparts. Hospital practice often deals with complex problems by having specialists for each problem. Our adult physician colleagues are beginning to realise that it doesn’t work and are reinventing the general physician.

It has been shown that community paediatric patients have significantly more complex problems than those presenting to general paediatricians. Many of the conditions we diagnose and treat have no diagnostic tests. Community paediatricians need excellent clinical skills, must be able to manage complexity and uncertainty, and must have the ability to communicate across disciplines and across agencies, creating understanding in those who come from different backgrounds and with different agendas. It is not an easy job.

The National Service Framework

The NSF was constructed by multidisciplinary groups including parents. It is therefore no accident that child health, not illness, is emphasised. Hospital practice has rather less emphasis than crosscutting “out of hospital” issues. Communication, coordination, and early intervention are all key themes. Parents and our sister agencies value medical input that is holistic, available where it is needed (not just in the clinic), and attuned to the needs of the child and family in the community. They demand more of it than we can currently give. Nevertheless, child health outside hospital has moved up the agenda and it will be hard for local authorities to deliver Every Child Matters without focused child health support to education, social, and voluntary services, as well as child health services.

This new agenda requires exactly the skills community paediatricians have. If community paediatricians did not exist, it would be necessary to invent them to deliver the NSF. The challenge is how we tackle it.

Dr C M Ni Bhrolchain
Consultant Community Paediatrician, Wirral Hospital NHS Trust, UK; cliona_nib@lineone.net

Competing interests: Dr Ni Bhrolchain in a Specialty Training Advisor in Community Child Health. These views are her own.

References


Melatonin: a panacea for desperate parents? (Hype or truth)

Sleep disorders are common in children with neurodevelopmental disorder and are a major source of stress for the whole family. In children with neurodevelopmental disabilities the prevalence may be as high as 80%. The current literature is suggestive of circadian rhythm dysfunction, social difficulties, and abnormal melatonin levels in children with autism.

Hypnotics and sedatives can produce side effects and tolerance, so is melatonin the answer in children with sleep problems associated with severe developmental difficulties of social and communicating nature, which have not responded to behavioural and social measures? Previous studies and case reports have suggested that melatonin could be effective.

We retrospectively reviewed cases of nine autistic children with chronic sleep disorder, who were attending the Child Development Centre at Windmill Lodge. The age range of these children was 2–11 years. No additional non-pharmacological sleep intervention was instituted. They were started on 2.5–5 mg melatonin 45 minutes before their sleeping time. In four of these patients sleep latency was reduced. Our own experience of reduction in sleep latency is in accordance with literature. Five parents reported improvement in total duration of sleep. In
three patients medication was stopped within a week because of no response. Four patients are still on melatonin for over a year without any side effects. We could not find the cause in non-responders.

To find out the real benefit of melatonin, the dose, short and long term side effects, and group of patients who will respond to melatonin, several authors have already identified the need for a double blind cross-over study. Previous studies have reported response rates of up to 80%, but it seems likely that studies which group together children with "neurodevelopmental disorders" in a generic manner will not furnish the answer as to the true place of melatonin in the management of disturbed sleep patterns.

The Children Act 2004 sets out a new framework for children's services with Directors of Children's Service and Lead Members for children in each local authority. The government is establishing Children's Trusts to drive the coordination and integration of planning, commissioning, and delivery of health, social care, and education services. How are these agencies to work together more effectively? There are well recognised facilitators and barriers to coordinating multi-agency practice. Poor communication between agencies and a lack of understanding of each other's roles and responsibilities has been a barrier and is a recurring feature in reports of child abuse and child deaths.

An integrated care pathway (ICP) is a health sector concept that "determines locally agreed multidisciplinary practice based on guidelines and evidence, where available, for a specific patient user group. It forms all or part of the clinical record, documents the care given and facilitates the evaluation of outcomes for continuous quality improvement". The ICP concept is multifaceted and complex but consists of both a process (of development and continuing maintenance) and a set of operational products. It can usefully be extended as a tool to improve multi-agency working.

An ICP to promote the health of looked after children has been developed in Birmingham. The products include a process map, updated health assessment documentation, and a variance reporting strategy. At its best an ICP can be a mechanism to enhance collaborative working across agencies for specific populations such as looked after children

References

An integrated care pathway for looked after children can facilitate multi-agency coordination

Looked after children are a vulnerable population at risk of unidentified and unmet health needs. Coordinated input from health, social care, and education services for these children is required by government but is not easily achieved. The focus on looked after children has sharpened with the Quality Protects programme, a major initiative launched in 1998 to improve their life chances. In 2002, the Department of Health (DH) published guidance on how to develop a health service for looked after children.

"Children in special circumstances", including looked after children, are prominent in the National Service Framework (NSF) for Children, Young People, and Maternity Services. Implementation of the DH guidance is explicitly required by the NSF.

The DVD uses an interface which will be familiar to most. Seven menus, covering the top presenting emergency symptoms in childhood, function as gateways to symptoms based tutorials. This simple menu system is useful to get to a particular section quickly. But there is no opportunity to interact with clinical material or cases, or for making management decisions.

The opening sequence contains many of the images we will see during the DVD set to an almost non-stop stream of melatonin in the sleep of sick children. The music is genial and immersive providing an appropriate background for the look at children's sleep. The DVD makes interesting watching and can be a fun and up-beat speciality. Most sick children do get better!...
but am in trouble if they defiantly say “no!”. I did not find any tips to deal with children who are difficult to examine. One highlight among the many excellent clips showing physical signs was the examination of the child with peritonitis. He winces and holds his abdomen rigid, even pushing the examining hand away. Watching such an examination is then next best thing to examining the child yourself, certainly better than a didactic session on clinical examination.

This DVD is a powerful, versatile, and informative resource which will be able to offer many healthcare professionals in all specialties and at all levels of training insight into how an ill child might look in practice. This is most useful in current times with the usual arguments over reduced time in training and the reduction in working hours. Anyone would feel more skilled after spending time with this DVD. I hope it will help to demystify the paediatric assessment and give those clinical signs which we strive to explain a real and “live” feel. This DVD, with its instructive and common-sense approach, should take pride of place in induction programmes and would be a valuable teaching resource in any A&E department, paediatric unit, or GP surgery. Overall it definitely does what it says on the box.

Immunization in practice, a practical guide for health staff


There have been some great successes in global immunisation in the last decade with the near eradication of polio and reductions in neonatal tetanus. In some developing countries childhood immunisation coverage is increasing, but in others it is still extremely low; for example, only 50% of infants in Sub-Saharan Africa compared to the United Nations goal of 90%. There is still great inequality between wealthy and low income countries in access to and delivery of safe vaccines. Thus there are millions of the most vulnerable children at risk of life threatening and disabling diseases.

The challenge of global immunisation

Leaving political and economic problems aside, how can immunisation rates in developing countries be improved and sustained? This book aims to provide a resource of practical and management skills to health workers in developing countries to reach this goal, and could equally be used as a training manual. It is the result of work between many organisations including the WHO, Children’s Vaccine Program, and UNICEF. It covers the common target diseases and their vaccines, and aims to promote the use of underused vaccines such as Hib, yellow fever, and hepatitis B. The immunisation schedule is based on the “Expanded Programme on Immunisation” and includes combination vaccines, for example, DTP–Hep B + Hib. The book version of this is used in conjunction with up to date national policies and vaccine schedules, which vary between countries and are regularly changing as new vaccines are introduced. The book is divided into eight modules with summary tables to highlight key points and clear diagrams. It covers the practical aspects of delivering effective immunisation in great detail, for example, the cold chain including details of transport and refrigeration. It explains how to make a homemade sharps container and how to dispose of them, from incineration to burying in a disposal pit. Information on the diseases, vaccines, and side effects is quite brief, but practical.

The module on holding an immunisation session emphasises safe practice to reduce needle stick injuries, including how to set up a clinic, injection techniques, and adopting autodisable syringes to prevent reuse. Strategies are listed to improve coverage by developing a district plan, fixed, outreach, and mobile clinics, estimating vaccine needs, and on building links with the local community. Further modules cover the monitoring and recording of data. This book is designed for developing countries and would be less useful for health professionals in the UK. It does not cover many of the new vaccines used in the UK, for example, conjugated pneumococcal or meningococcal vaccines, which are not priorities in developing countries. However, the practical sections on holding an immunisation session set clear quality standards which should be adopted by any organisation delivering an immunisation clinic. Up to date information on the UK immunisation schedule can be found online in the “Green Book” and its updates at http://www.immunisation.nhs.uk/ under the publications section. The full version of this book can be found online at http://www.who.int/vaccines-documents/DoxTrng/h4iip.htm. Overall this book will be a valuable tool in the global challenge of delivering safe and effective immunisation to all children.

Reece

Key topics in neonatology, 2nd edition


The second edition of Key topics in neonatology claims to provide a quick and very up to date summary of current concepts in neonatology, in a self contained and easily readable problem based format for neonatal trainees and nurses. The authors recommend the text as an ideal revision aid for MRCPCH and DCH candidates. The book is very compact and has just over 400 pages, with common neonatal problems arranged alphabetically, which we found easy to use.

The authors do acknowledge that some topics reflect their personal practice; however each topic ends with a useful reading list and related topics of interest, which encompasses other contemporary views. References to family support groups are also helpful.

The majority of sections give good, clear, concise advice and certainly fulfil the role of a revision text. However, we found it disappointing to have seen cardiac tamponade included as a cause, in the section on acute neonatal collapse, and the use of echocardiography in the list of investigations to exclude this. The section on ambiguous genitalia was weak, mainly because of the incorrect view of those cases being females with congenital adrenal hyperplasia. The authors have decided to cling on to outdated terms such as “nisiplier blossom” and “hermaphrodite”, and the PAGC classification given for grading of intracranial haemorrhage.

Because of the problem based format, some topics were necessarily repeated, and there were some inconsistencies in recommendations in different sections of the book. For example, hepatitis B immunoglobulin is recommended to be given within 24 hours in one section and within 48 hours in another. The normal anion gap is given as 6–14 in one place and as 8–16 in another. Inconsistencies were also noted in cord haemoglobin and bilirubin values for recommended early exchange transfusion.

There was an excellent “special notes” section with a discussion of the appropriateness of different types of volume replacement and inotropes in hypotension. We would have liked to see similar sections surrounding some other controversial subjects and management issues. Despite suggesting that saline should be the usual fluid of choice, it appears that the authors’ practice is to use blood products in their clinical management, in other areas of the text. We decided to do a test run using the book to see if it matched up with the authors’ claims that it is a quick reference book in the neonatal unit, by referring to the book, to guide us in management on a few admissions to the neonatal unit.

The first clinical scenario was a baby whose mother was diagnosed with maternal HIV after delivery. In less than a minute we had detailed information on perinatal HIV management along with web addresses of useful links—impressive indeed! Unfortunately in the five page chapter on HIV, only half a page was dedicated to neonatal prophylaxis. There is no mention about the ethical and legal issues when a mother refuses postnatal HIV testing. The text did not help in the management of the baby in this case; however the cited excellent website of ‘Bliva’ came to the rescue in deciding what pre-treatment need to be given.

The second scenario was a baby with pulmonary hypertension where we wanted check formulas for oxygenation index and AaDO2. Again within seconds, everything was in front of us. Although we wanted to check the length to which umbilical arterial catheter should be inserted for this baby, we were disappointed as there was no mention of a formula anywhere.

The third scenario was the counselling of a mother with antenatally diagnosed ventriculomegaly in the fetus. Unfortunately this was not mentioned anywhere in the book. However, there was very detailed information on the “Epicure study” and neurodevelopmental outcome of babies born at extremes of viability. This will be very handy information for neonatal registrars in counselling expectant mothers in preterm labour.

The final scenario for the run was to ascertain the investigation and drug therapy for an 8 week old premature baby with conjugated jaundice. The topic is described in great detail under both jaundice and liver disorders, and there is a huge list of causes of neonatal hepatitis. Inclusion of conditions such as erythropoietic
Prevention of allergy and allergic asthma: World Allergy Organization project report and guidelines


Edited by two Scandinavian experts in the field, this book is the result of a working group of the World Allergy Organization (WAO) and the WHO. With contributions by authors from 21 countries it presents a contemporary international overview and consensus of what is known and not known about prevention (primary, secondary, and tertiary) of allergic disorders.

The introduction includes clear definitions of some terms such as allergy and hypersensitivity. It also sets out the useful instruction to all the authors to include an evidence base category with all references—and this book cannot be criticised for a lack of references!

The genetics of allergy are then reviewed in detail that is moderately technical but highlights some of the problems with the results from research to date, such as the varying definitions of atopy (that is, phenotype definition) used in different studies. Despite much effort and the advance of molecular biology, there are still few new certainties about the inheritance of allergy, but strategies for future work are described.

Unsurprisingly, the longest chapter in the book analyses proposed environmental influences causing asthma and allergy. Various dietary factors from fish oils to food additives are discussed. Topical issues such as the hygiene hypothesis, the influence of immunisations, antibiotics, and probiotics (live microbial food components) are all examined and the data presented concisely. What is known about the benefits of breast feeding and weaning is also summarised. The clearest conclusion is that environmental tobacco smoke is bad for allergic Airways disease and more governmental action is required.

Another chapter reviews the fascinating issue of immunological influences on the fetus and neonate, showing that significant immune responses occur in utero, influenced by passage of allergen from mother to fetus.

Subsequently, the interventions in infants at high risk of developing allergy are concisely analysed with regard to altering maternal diet during pregnancy and lactation and reducing household aeroallergens. Of clinical relevance is the conclusion that there is no evidence of a preventative benefit of soy based compared with cows’ milk formulae.

“Can I do anything to stop my child getting asthma and/or eczema” is a concern of an increasing number of parents. Paediatricians, who are often faced with this question, do not have easy access to specialist allergy opinion at present, because allergy as a medical speciality in the UK could itself be considered to suffer from “failure to thrive”.

Any paediatrician or clinician with an interest in asthma, eczema, or food allergy (are there any who don’t?) will find this book helpful. For anyone drafting local ward and/or community guidelines for nutrition, weaning, and allergy, it provides an evidence base and also some suggested information sheets and guidelines.

A minor criticism is that the subject index suffers from restricted development.

In conclusion, this book would be a useful resource for those interested in allergy within specialist departments and also for reference to the general paediatrician with an interest.

I Pollock

CORRECTION

do: 10.1136/adc.2003.032052corr1

Kendrick D, Royal S. Cycle helmet ownership and use; a cluster randomised controlled trial in primary school children in deprived areas (Arch Dis Child 2004;89:330–5). There were two errors in the sample size calculation for this article. The correct figures should be 93% (not 90% in the calculation for helmet owning) and 48.5% (not 44.5% in the calculation for helmet wearling). Therefore, the sample size calculation should read:

The study had 80% power to detect a difference in the percentage of children owning a helmet from 81% to 93% between the 2 treatment groups.

and

It had 80% power to detect a difference in the percentage of children always wearing a helmet from 34% to 48.5%, at the 5% significance level.